Gemcabene

Drug Profile

Gemcabene

Alternative Names: CI-1027; PD 0072953; PD 072953

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer Gemphire Therapeutics; Pfizer
  • Class Antihyperlipidaemics; Caproates; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors; Lipoprotein A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Hyperlipoproteinaemias; Hypertension; Hypertriglyceridaemia; Osteoarthritis
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Aug 2017 Interim efficacy and adverse events data from a phase IIb ROYAL-1 trial in Hypercholesterolaemia released by Gemphire Therapeutics
  • 07 Aug 2017 Gemphire therapeutics completes the phase IIb ROYAL-1 trial for Hypercholesterolaemia in USA
  • 28 Jun 2017 Gemphire Therapeutics completes the phase II COBALT-1 trial for Hypercholesterolaemia in USA, Canada and Israel (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top